Therefore, HER2+ breast cancer patients were categorized as sensitive (pCR achieved) or resistant (pCR did not achieve) to neoadjuvant chemotherapy and were used as an RNA-seq strategy to identify predictors of pCR. Here, ERBB2 is linked to breast cancer.